SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is experiencing significant price volatility, largely attributed to geopolitical concerns impacting major South Korean memory producers, despite strong bullish sentiment surrounding its sold-out High-Bandwidth Memory (HBM) supply for AI infrastructure through 2027 and recent analyst target increases.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending as the escalating Middle East conflict and its impact on global oil supplies fuel market volatility, leading to intense community discussion around the US market's perceived resilience and "V-shaped" recoveries despite significant sell-offs in Asian markets.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending amidst escalating geopolitical tensions in the Middle East, with community discussion focused on the potential for a prolonged conflict and its impact on global oil supply. Traders are actively debating whether the market's current volatility will lead to a significant downturn, particularly given sharp declines observed in Asian markets.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is actively discussed amid escalating US-Israel-Iran tensions and concerns over oil supply, creating a divided community perspective between those fearing a broader market downturn and others anticipating a resilient "buy the dip" bounce.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amidst significant volatility driven by its delayed earnings report, which fuels investor uncertainty, alongside recent geopolitical noise, including the briefly reinstated Pentagon list and ongoing tariff discussions. Despite this, the launch of its upgraded Qwen 3.5 AI model and deeply oversold technicals are sparking community debate over whether it presents a compelling 'buy the dip' opportunity.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is experiencing extreme community frustration due to its persistent underperformance and new 52-week lows, with many questioning management's strategy and the impact of intense market competition. Investors are keenly anticipating upcoming earnings to see if deep undervaluation, fueled by substantial cash and revenue, will finally translate into a turnaround, or if further declines are in store.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to heightened community speculation about a significant buyout by a major pharmaceutical company, fueled by optimism that its GPS cancer treatment is showing exceptional patient survival in its ongoing Phase 3 trial and a potential short squeeze given high interest.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. is attracting significant attention due to a recent press release and live product deployment, with the community actively speculating on a potential short squeeze. Elevated short interest and exorbitant cost-to-borrow rates are fueling this buzz, as many anticipate continued strong performance.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is actively discussed following its earnings report, which, despite beating some estimates and announcing a $400 million share repurchase, also included weaker guidance on future growth, sparking a polarized reaction. While many express concern over slowing growth and potential competition from AI, others view the sell-off as an overreaction and are keenly watching for a potential acquisition amidst persistent buyout rumors.

Kamino Finance was originally created to offer users the easiest possible way of providing liquidity and earning yield on-chain.  The protocol's one-click, auto-compounding concentrated liquidity strategies quickly became the most popular LP products on Solana, and laid the foundation for what Kamino is now.  Today, Kamino is a first-of-its-kind DeFi protocol that unifies Lending, Liquidity, and Leverage into a single, secure DeFi product suite.

Kamino

KMNO Crypto is generating significant buzz following its partnership with Anchorage Digital Bank, which integrates regulated custody with Solana's on-chain lending, driving a notable increase in volume. The community is actively discussing its low market cap and strong fundamentals as a leading DeFi protocol on Solana, positioning it as a potential "sleeping giant" for substantial growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) Director Kevin Tang purchased 516,439 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, February 27th. The...

GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH

GSA Capital Partners LLP trimmed its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) by 95.9% in the 3rd quarter, according to its most recent 13F filing with the...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.53 earnings per share (EPS) for the quarter...

Aurinia Pharmaceuticals Q4 Earnings Call Highlights

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported fourth-quarter and full-year 2025 results on its latest earnings call, highlighting continued growth from its lupus nephritis therapy LUPKYNIS and...

Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +25.79% and +3.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.</li><li>LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.</li><li>Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.</li></ul>Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Active Lupus Nephritis Therapy Sales Gain Momentum</h2>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user called Aurinia’s earnings and cash position “solid.”<stembedurl>https://stocktwits.com/VSTN/message/645950955</stembedurl>Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.<stembedurl>https://stocktwits.com/Ballerdad1/message/645950749</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down 10% year-to-date, but up 80% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/celh-stock-soaring-today-celsius-q4-earnings-beat/cZTG9gDRIb8">CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Equity

Earnings Summary: Aurinia Pharmaceuticals Q4

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial...

Earnings Preview: Aurinia Pharmaceuticals

United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of +13.50% and -1.88%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

Investor Tang has significantly increased his stake to ~18% voting power, sparking speculation about a major catalyst or management changes.

Shareholders are vocalizing strong discontent with the CEO, pushing for accountability and potential changes in leadership amid performance and transparency concerns.

High off-exchange short volume and recent spikes in trading activity are fueling predictions of an impending short squeeze and price rally.

Traders are keenly awaiting an update on the AUR200 clinical trial, believing clarity on its status is crucial for future share price momentum.

Current Price	$14.15
Prev Close	$14.21
Open	$14.09
Dividend Yield	0.00%
50-Day Moving Average	$15.00
Beta	0.87
Avg. Volume	899,237.89
PE Ratio	6.84

52-Week High	$16.54
52-Week Low	$6.83
Market Capitalization	$1.89B
EPS (Annual)	$2.07
Price to Book	3.23
Revenue Per Employee	$2.21M

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc